Lenalidomida Teva

Lenalidomide, the active ingredient in Lenalidomida Teva, is an immunomodulatory drug presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes with 5q deletion in adult patients.

GNH USA supplies Lenalidomida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenalidomide is an immunomodulatory antineoplastic that targets malignant plasma cells and dysplastic hematopoietic clones.

Multiple Myeloma: improves response rates and prolongs progression‑free survival in eligible adults. Myelodysplastic Syndromes with 5q deletion: reduces transfusion dependence and induces cytogenetic remission.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Nausea: mild to moderate gastrointestinal upset.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers during therapy.

Before initiating therapy, clinicians should assess baseline laboratory values and risk factors.

Monitor blood counts: perform regular CBCs to detect cytopenias. Assess thromboembolic risk: consider prophylactic anticoagulation when indicated. Evaluate renal and hepatic function: adjust therapy if impairment is present. Avoid in pregnancy: teratogenic potential requires strict contraception. Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunomodulation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - NSAIDs: additive effect on platelet inhibition. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity.